""What we see here is when we give this drug [genistein], we decrease the cardiac inflammation or the myocarditis,""
""However, we still keep the protective properties of the vaccine to protect against COVID.""
""We have no FDA-approved treatments for myocarditis,""
""Having models like this, where we can understand the mechanisms that drive myocarditis, allow us to think how we can specifically target inflammation to treat patients with it.""
Shorter intervals between mRNA vaccine doses may raise myocarditis risk, and spacing doses could blunt immune spikes that stress the heart. Estrogen appears to reduce inflammatory damage in mice after a cytokine surge, which motivated testing genistein, a plant-based phytoestrogen from soy, that similarly lowered inflammation in laboratory models. Genistein reduced cardiac inflammation while maintaining vaccine protective effects. There are currently no FDA-approved treatments for myocarditis. Developing models that clarify myocarditis mechanisms can guide targeted anti-inflammatory therapies and inform design of safer mRNA vaccines.
Read at Kqed
Unable to calculate read time
Collection
[
|
...
]